Elias Ortega Chahla, Medical Director (Hematology/Oncology), IQVIA, shared a post on LinkedIn:
“Excited to share our work presented at SNOLA Society for Neuro-Oncology Latin America in São Paulo, 2026!
Our team conducted a scoping review on therapeutic interventions for medulloblastoma in Latin America and the Caribbean (LAC), aiming to better understand the current landscape and identify critical gaps in care and research.
Why this matters
Medulloblastoma is the most common malignant pediatric CNS tumor, with survival rates reaching up to 85% in high-resource settings. However, our findings highlight a very different reality across LAC.
Key insights from our study:
- Evidence is fragmented and concentrated mainly in Brazil and Mexico.
- Overall survival (27–77%) and PFS/EFS (34–70%) are lower than international benchmarks.
- Limited molecular characterization (only ~23% of studies).
- Delays in treatment initiation and heterogeneity in surgical approaches.
- Treatment abandonment rates up to 61%
What’s needed next:
To move toward equitable, precision-based care in the region, we emphasize:
- Stronger multicenter collaboration across LAC.
- Standardized reporting and data generation.
- Broader access to molecular diagnostics.
- Integration of quality-of-life outcomes.
- Addressing social determinants of treatment abandonment.
This work underscores the urgent need to bridge disparities and build context-specific solutions for children affected by brain tumors in our region.
Grateful to collaborate with such an incredible team, specially Matías Agustín Atencio, MD.”
Other articles featuring Elias Ortega Chahla on OncoDaily.